Li-Juan Zong

发表

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS

YU Peng, Saijuan Chen, Zhu Chen, 2020, Blood.

Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia

YU Peng, Jun Shi, Saijuan Chen, 2022, Cell Research.

Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia

H. Qiu, Jian Zhang, J. Kong, 2022, Leukemia & lymphoma.

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

YU Peng, Kai Xue, Bing Chen, 2022, Leukemia.

SETD2 deficiency predicts poor prognosis in MDS and accelerated MDS-associated leukemogenesis via S100a9.

Saijuan Chen, Zhu Chen, Ming Sun, 2020, Blood.

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia

Depei Wu, H. Qiu, Jian Zhang, 2021, Annals of Hematology.

Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients

Depei Wu, H. Qiu, Jian Zhang, 2023, Molecular carcinogenesis.

ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS.

Cheng-Long Hu, Juan Guo, Lingyun Wu, 2023, Science Advances.

SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis.

Kai Xue, Cheng-Long Hu, Xiaojian Sun, 2024, Developmental cell.